Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shirin Rizzardo

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
JAMA Health Forum|October 11, 2024
Competition in International Generic Drug MarketsÉtienne Gaudette, Shirin Rizzardo, Kevin R Pothier, et al.
BMJ Open|March 14, 2024
Cost-effectiveness of the top 100 drugs by public spending in Canada, 2015-2021: a repeated cross-sectional studyÉtienne Gaudette, Shirin Rizzardo, Yvonne Zhang, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 5, 2023
Étienne Gaudette, Shirin Rizzardo, Sasha B Wladyka, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 12, 2023
Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada reviewÉtienne Gaudette, Shirin Rizzardo, Sasha B Wladyka, et al.
The Patient|January 15, 2015
Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference surveyNick Dragojlovic, Shirin Rizzardo, Nick Bansback, et al.
Healthcarepapers|January 24, 2023
Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by EveryoneSandra Sirrs, Helen Anderson, Bashir Jiwani, et al.
Healthcarepapers|January 24, 2023
Expensive Drugs for Rare Diseases in Canada: What Value and at What Cost?Sandra Sirrs, Helen Anderson, Bashir Jiwani, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 6, 2019
Evaluating Canadians' Values for Drug Coverage Decision MakingShirin Rizzardo, Nick Bansback, Nick Dragojlovic, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
JAMA Health Forum|October 11, 2024
Competition in International Generic Drug MarketsÉtienne Gaudette, Shirin Rizzardo, Kevin R Pothier, et al.
BMJ Open|March 14, 2024
Cost-effectiveness of the top 100 drugs by public spending in Canada, 2015-2021: a repeated cross-sectional studyÉtienne Gaudette, Shirin Rizzardo, Yvonne Zhang, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 5, 2023
Étienne Gaudette, Shirin Rizzardo, Sasha B Wladyka, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 12, 2023
Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada reviewÉtienne Gaudette, Shirin Rizzardo, Sasha B Wladyka, et al.
The Patient|January 15, 2015
Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference surveyNick Dragojlovic, Shirin Rizzardo, Nick Bansback, et al.
Healthcarepapers|January 24, 2023
Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by EveryoneSandra Sirrs, Helen Anderson, Bashir Jiwani, et al.
Healthcarepapers|January 24, 2023
Expensive Drugs for Rare Diseases in Canada: What Value and at What Cost?Sandra Sirrs, Helen Anderson, Bashir Jiwani, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 6, 2019
Evaluating Canadians' Values for Drug Coverage Decision MakingShirin Rizzardo, Nick Bansback, Nick Dragojlovic, et al.
Pageof 1